Document Detail


Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry.
MedLine Citation:
PMID:  16996869     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sirolimus-eluting stents (SESs) have been shown to decrease restenosis compared with bare metal stents (BMSs). Currently, there are limited data on the long-term efficacy of these devices in a real-world patient population. Furthermore, the potential of a late restenotic phenomenon has not yet been excluded. From April to October 2002, 508 consecutive patients with de novo lesions exclusively treated with SESs were enrolled and compared with 450 patients treated with BMSs in the preceding 6 months (control group). Patients in the SES group more frequently had multivessel disease and type C lesions, received more stents, and had more bifurcation stenting. After 3 years, the cumulative incidence of major adverse cardiac events (comprising death, myocardial infarction, and target vessel revascularization) was significantly lower in the SES group compared with the pre-SES group (18.9% vs 24.7%, hazards ratio 0.73, 95% confidence interval 0.56 to 0.96, p = 0.026). The 3-year risk of target lesion revascularization was 7.5% in the SES group versus 12.6% in the pre-SES group (hazards ratio 0.57, 95% confidence interval 0.38 to 0.87, p = 0.01). In conclusion, the unrestricted use of SESs is safe and superior to the use of BMSs. The beneficial effects, reported after 1 and 2 years in reducing major adverse cardiac events, persisted with no evidence of a clinical late restenotic "catch-up" phenomenon.
Authors:
Joost Daemen; Andrew T L Ong; Giulio G Stefanini; Keiichi Tsuchida; Helle Spindler; Georgios Sianos; Peter P T de Jaegere; Ron T van Domburg; Patrick W Serruys
Related Documents :
17643519 - Effects of levosimendan versus dobutamine on long-term survival of patients with cardio...
2627949 - Results of repeat angiography up to eight years following percutaneous transluminal ang...
18158289 - One-year clinical outcomes with abciximab vs. placebo in patients with non-st-segment e...
17409579 - Initial and long-term outcomes of sirolimus-eluting stents for calcified lesions compar...
11352879 - Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-rad...
18317669 - Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospe...
18292849 - Increasing the use of anti-inflammatory agents for acute asthma in the emergency depart...
23490989 - Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering wald...
15274199 - Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis.
Publication Detail:
Type:  Journal Article     Date:  2006-08-07
Journal Detail:
Title:  The American journal of cardiology     Volume:  98     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-25     Completed Date:  2006-11-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  895-901     Citation Subset:  AIM; IM    
Affiliation:
The Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Angina, Unstable / epidemiology
Angioplasty, Balloon
Case-Control Studies
Coronary Restenosis / prevention & control*
Diabetes Mellitus / epidemiology
Female
Follow-Up Studies
Humans
Hypertension / epidemiology
Immunosuppressive Agents / administration & dosage*
Male
Middle Aged
Myocardial Infarction / epidemiology
Myocardial Revascularization
Netherlands / epidemiology
Prosthesis Design
Registries
Regression Analysis
Shock, Cardiogenic / epidemiology
Sirolimus / administration & dosage*
Stents*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictors of development of diabetes mellitus in patients with coronary artery disease taking antih...
Next Document:  Effect of heparin on blood vascular endothelial growth factor levels in patients with ST-elevation a...